Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020
EP. 1: Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 2: OLKIOS: Looking at Ofatumumab’s Continued Efficacy
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 3: OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 4: Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 5: Takeaways From ACTRIMS-ECTRIMS 2020 Meeting
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 6: Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 7: OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 8: OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 9: Ozanimod Compared to Teriflunomide Utilizing Statistical Matching
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 10: Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 11: Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 12: Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 13: CLARITY Extension Trial: Disability Improvement With Cladribine
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 14: COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
EP. 15: Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative
ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD 
